David Wayne Robinson - 21 Jan 2026 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Reporting relationship: Global CCO
Issuer ticker: OCUL
Reported as of: 21 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Jan 2026, 19:15:21 UTC
Source filing: View source filing
Reporting owner signature: /s/ Todd Anderman, Attorney-in-Fact for David Wayne Robinson

Filing notes and source

Key filing fact

David Wayne Robinson filed Form 4 for OCULAR THERAPEUTIX, INC (OCUL) on 26 Jan 2026.

Key facts

This page summarizes David Wayne Robinson's Form 4 filing for OCULAR THERAPEUTIX, INC (OCUL).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 26 Jan 2026, 19:15.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002107335 Primary reporting owner

Robinson David Wayne

Relationship: Global CCO
Address: C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD
Signature: /s/ Todd Anderman, Attorney-in-Fact for David Wayne Robinson
Signature date: 26 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OCUL transaction

Common Stock

Award

Transaction value: $0
Shares: +136,000
Change %
Price: $0.000000
Shares after: 136,000
Date: 21 Jan 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OCUL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +416,000
Change %
Price: $0.000000
Shares after: 416,000
Date: 21 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 416,000
Exercise price: $11.42
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On January 21, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2019 Inducement Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.

Footnote F2

This option was granted on January 21, 2026 and vests over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the reporting person's first date of employment and the remainder vesting in equal monthly installments over the three years after such date.